An association between liraglutide treatment and reduction in excessive daytime sleepiness in obese subjects with type 2 diabetes.

Gomez-Peralta F, Abreu C, Castro JC, Alcarria E, Cruz-Bravo M, Garcia-Llorente MJ, Albornos C, Moreno C, Cepeda M, Almodóvar F

BMC endocrine disorders4 Dec 2015Cited by 28 (Europe PMC)

PMID26637348PMCIDPMC4669657DOI10.1186/s12902-015-0074-6PepBankPUB-26637348

Download PDF PubMedAsk about this study

Jump to 11 results

Summary

BackgroundThe main purpose of the present study is to evaluate whether treatment with long-acting human glucagon-like peptide-1 liraglutide was associated with an improvement of excessive daytime sleepiness (EDS) in obese subjects with type-2 diabetes.MethodsThis single-centre retrospective study included 158 obese (body mass index [BMI] ≥ 30 kg/m(2)) adult subjects with type-2 diabetes who were initiated with liraglutide treatment at least 3 months before study inclusion. Data of the Epworth Sleepiness Scale (ESS), anthropometric parameters, glucose-control and metabolic parameters were collected at liraglutide initiation (baseline) and at months 1 and 3 after liraglutide initiation.ResultsSignificant reductions in ESS score were achieved at months 1 (-1.3 ± 2.8, p < 0.001) and 3 (-1.5 ± 3.0, p < 0.001) after liraglutide introduction. After 3 months of treatment with liraglutide, significant changes in body weight (p < 0.001), BMI (p < 0.001), waist (p < 0.001) and neck circumferences (p < 0.005), HbA1c (p < 0.001), mean blood glucose (p < 0.001), fasting plasma glucose (p < 0.001), triglycerides (p < 0.01) and total cholesterol (p < 0.001) were achieved.ConclusionsAfter 3 months of treatment with liraglutide a significant reduction in EDS was observed in obese subjects with type-2 diabetes. Besides this, significant changes in body weight and metabolic parameters of diabetes control were also accomplished. Further investigation is required to determine whether liraglutide could improve other abnormal sleep patterns and obstructive sleep apnoea.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

01HumanObservational studyEfficacy outcome
In obese adults with type 2 diabetes, ESS score fell significantly at month 1 after starting liraglutide.
In plain wordsIn obese adults with type 2 diabetes, daytime sleepiness scores were lower 1 month after starting liraglutide.
Peptide
Liraglutide
Outcome
DecreaseEpworth Sleepiness Scale (ESS) score at month 1
Study
n = 158
Comparator
Baseline
Outcome group
Sleep · Sleep
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Measurements
ESS score change
−1.3 points
month 1
Source sentences
Summary
Significant reductions in ESS score were achieved at months 1 (-1.3 ± 2.8, p < 0.001) and 3 (-1.5 ± 3.0, p < 0.001) after liraglutide introduction.
1 context sentence(design, population, supporting numbers)
Summary · context
This single-centre retrospective study included 158 obese (body mass index [BMI] ≥ 30 kg/m(2)) adult subjects with type-2 diabetes who were initiated with liraglutide treatment at least 3 months before study inclusion.
Show in the study text Report a problemFND-2663734801
02HumanObservational studyEfficacy outcome
In obese adults with type 2 diabetes, ESS score fell significantly at month 3 after starting liraglutide.
In plain wordsIn obese adults with type 2 diabetes, daytime sleepiness scores were lower 3 months after starting liraglutide.
Peptide
Liraglutide
Outcome
DecreaseEpworth Sleepiness Scale (ESS) score at month 3
Study
n = 158
Comparator
Baseline
Outcome group
Sleep · Sleep
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Measurements
ESS score change
−1.5 points
month 3
Source sentences
Summary
Significant reductions in ESS score were achieved at months 1 (-1.3 ± 2.8, p < 0.001) and 3 (-1.5 ± 3.0, p < 0.001) after liraglutide introduction.
1 context sentence(design, population, supporting numbers)
Summary · context
This single-centre retrospective study included 158 obese (body mass index [BMI] ≥ 30 kg/m(2)) adult subjects with type-2 diabetes who were initiated with liraglutide treatment at least 3 months before study inclusion.
Show in the study text Report a problemFND-2663734802
03HumanObservational studyEfficacy outcome
In obese adults with type 2 diabetes, body weight changed significantly after 3 months of liraglutide.
In plain wordsIn obese adults with type 2 diabetes, body weight changed significantly after 3 months of liraglutide.
Peptide
Liraglutide
Outcome
Direction not reportedBody weight
Study
n = 158
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
body weight (p < 0.001)
1 context sentence(design, population, supporting numbers)
Summary · context
This single-centre retrospective study included 158 obese (body mass index [BMI] ≥ 30 kg/m(2)) adult subjects with type-2 diabetes who were initiated with liraglutide treatment at least 3 months before study inclusion.
Show in the study text Report a problemFND-2663734803
04HumanObservational studyEfficacy outcome
In obese adults with type 2 diabetes, BMI changed significantly after 3 months of liraglutide.
In plain wordsIn obese adults with type 2 diabetes, BMI changed significantly after 3 months of liraglutide.
Peptide
Liraglutide
Outcome
Direction not reportedBMI
Study
n = 158
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
BMI (p < 0.001)
1 context sentence(design, population, supporting numbers)
Summary · context
This single-centre retrospective study included 158 obese (body mass index [BMI] ≥ 30 kg/m(2)) adult subjects with type-2 diabetes who were initiated with liraglutide treatment at least 3 months before study inclusion.
Show in the study text Report a problemFND-2663734804
05HumanObservational studyEfficacy outcome
In obese adults with type 2 diabetes, waist circumference changed significantly after 3 months of liraglutide.
In plain wordsIn obese adults with type 2 diabetes, waist size changed significantly after 3 months of liraglutide.
Peptide
Liraglutide
Outcome
Direction not reportedWaist circumference
Study
n = 158
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
waist (p < 0.001)
1 context sentence(design, population, supporting numbers)
Summary · context
This single-centre retrospective study included 158 obese (body mass index [BMI] ≥ 30 kg/m(2)) adult subjects with type-2 diabetes who were initiated with liraglutide treatment at least 3 months before study inclusion.
Show in the study text Report a problemFND-2663734805
06HumanObservational studyEfficacy outcome
In obese adults with type 2 diabetes, neck circumference changed significantly after 3 months of liraglutide.
In plain wordsIn obese adults with type 2 diabetes, neck size changed significantly after 3 months of liraglutide.
Peptide
Liraglutide
Outcome
Direction not reportedNeck circumference
Study
n = 158
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
neck circumferences (p < 0.005)
1 context sentence(design, population, supporting numbers)
Summary · context
This single-centre retrospective study included 158 obese (body mass index [BMI] ≥ 30 kg/m(2)) adult subjects with type-2 diabetes who were initiated with liraglutide treatment at least 3 months before study inclusion.
Show in the study text Report a problemFND-2663734806
07HumanObservational studyEfficacy outcome
In obese adults with type 2 diabetes, HbA1c changed significantly after 3 months of liraglutide.
In plain wordsIn obese adults with type 2 diabetes, HbA1c changed significantly after 3 months of liraglutide.
Peptide
Liraglutide
Outcome
Direction not reportedHbA1c
Study
n = 158
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
HbA1c (p < 0.001)
1 context sentence(design, population, supporting numbers)
Summary · context
This single-centre retrospective study included 158 obese (body mass index [BMI] ≥ 30 kg/m(2)) adult subjects with type-2 diabetes who were initiated with liraglutide treatment at least 3 months before study inclusion.
Show in the study text Report a problemFND-2663734807
08HumanObservational studyEfficacy outcome
In obese adults with type 2 diabetes, mean blood glucose changed significantly after 3 months of liraglutide.
In plain wordsIn obese adults with type 2 diabetes, average blood sugar changed significantly after 3 months of liraglutide.
Peptide
Liraglutide
Outcome
Direction not reportedMean blood glucose
Study
n = 158
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
mean blood glucose (p < 0.001)
1 context sentence(design, population, supporting numbers)
Summary · context
This single-centre retrospective study included 158 obese (body mass index [BMI] ≥ 30 kg/m(2)) adult subjects with type-2 diabetes who were initiated with liraglutide treatment at least 3 months before study inclusion.
Show in the study text Report a problemFND-2663734808
09HumanObservational studyEfficacy outcome
In obese adults with type 2 diabetes, fasting plasma glucose changed significantly after 3 months of liraglutide.
In plain wordsIn obese adults with type 2 diabetes, fasting blood sugar changed significantly after 3 months of liraglutide.
Peptide
Liraglutide
Outcome
Direction not reportedFasting plasma glucose
Study
n = 158
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
fasting plasma glucose (p < 0.001)
1 context sentence(design, population, supporting numbers)
Summary · context
This single-centre retrospective study included 158 obese (body mass index [BMI] ≥ 30 kg/m(2)) adult subjects with type-2 diabetes who were initiated with liraglutide treatment at least 3 months before study inclusion.
Show in the study text Report a problemFND-2663734809
10HumanObservational studyEfficacy outcome
In obese adults with type 2 diabetes, triglycerides changed significantly after 3 months of liraglutide.
In plain wordsIn obese adults with type 2 diabetes, triglycerides changed significantly after 3 months of liraglutide.
Peptide
Liraglutide
Outcome
Direction not reportedTriglycerides
Study
n = 158
Comparator
Baseline
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
triglycerides (p < 0.01)
1 context sentence(design, population, supporting numbers)
Summary · context
This single-centre retrospective study included 158 obese (body mass index [BMI] ≥ 30 kg/m(2)) adult subjects with type-2 diabetes who were initiated with liraglutide treatment at least 3 months before study inclusion.
Show in the study text Report a problemFND-2663734810
11HumanObservational studyEfficacy outcome
In obese adults with type 2 diabetes, total cholesterol changed significantly after 3 months of liraglutide.
In plain wordsIn obese adults with type 2 diabetes, total cholesterol changed significantly after 3 months of liraglutide.
Peptide
Liraglutide
Outcome
Direction not reportedTotal cholesterol
Study
n = 158
Comparator
Baseline
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
total cholesterol (p < 0.001)
1 context sentence(design, population, supporting numbers)
Summary · context
This single-centre retrospective study included 158 obese (body mass index [BMI] ≥ 30 kg/m(2)) adult subjects with type-2 diabetes who were initiated with liraglutide treatment at least 3 months before study inclusion.
Show in the study text Report a problemFND-2663734811

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.